While cancers such as breast, lung, and prostate frequently dominate public health discussions, there is a far less recognised but equally aggressive form - sarcoma. It affects thousands across the UK ...

VCU Massey is the first U.S. site in a global phase 2a trial for PTX-100, targeting cutaneous T-cell lymphoma. The BIPAVE-001 trial is evaluating AI-081, a PD-1 and VEGF bispecific antibody, for ...

When most people think of cancer, names like breast, lung, or prostate cancer instantly come to mind. However, there’s another, lesser-known form called sarcoma that affects thousands of people in the ...

Lung cancer varies widely from patient to patient, and that diversity makes it hard to find effective treatments. Researchers ...

Moleculin Biotech, Inc. announced promising results from their Phase 1B/2 trial of Annamycin for treating soft tissue sarcoma lung metastases, showing a robust clinical benefit rate of 59.4% among ...

Survivors of non-small cell lung cancer are at risk for both second primary lung cancers as well as non-lung secondary ...

A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer ...

Thanks to recent therapy advances, the lung cancer mortality rate has declined and survival rates have improved. Many factors influence the likelihood of a lung cancer cure or long-term survival, ...

Current U.S. Preventive Services Task Force screening guidelines could exclude more than 60% of patients who develop lung cancer.Conversely, an age-based approach to screening could save more than 25, ...

Every July, Sarcoma Awareness Month reminds us of a cancer that’s often sidelined in public discourse. However, sarcoma is not just one disease, it is a group of rare cancers with over 150 subtypes, ...

A small subpopulation of highly plastic cancer cells has been found to be for cancer progression and treatment resistance.